angiotensin IV raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-01-13 and is reviewed periodically as new material appears.
Early laboratory work focused on its effects on synaptic connectivity and neuronal signaling. In cell and animal models, dihexa has been reported to promote the formation of new synapses, a process called synaptogenesis. These findings have generated interest in cognitive research, but the evidence base remains mostly preclinical. Human clinical trials with clear safety and efficacy endpoints are limited or absent in the public literature. Whether these effects translate to humans is an open question.
The proposed mechanism involves interaction with the hepatocyte growth factor (HGF) system and its receptor, c-Met. Dihexa is described in some studies as an HGF mimetic, meaning it may mimic or enhance HGF-mediated signaling. Activation of c-Met can influence cell growth, survival, and cytoskeletal remodeling, pathways that intersect with synaptic plasticity. However, the precise binding targets and downstream events for dihexa are not fully established, and alternative mechanisms have been suggested.
Dihexa is a synthetic peptide with the chemical name N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, and it is structurally related to angiotensin IV, a naturally occurring peptide fragment. Researchers developed it as a modified analog intended to alter stability and activity relative to the parent peptide. Its short sequence and fatty acid chain distinguish it from many endogenous peptides, and published studies often describe it under the abbreviation dihexa. The compound is classified as a laboratory compound rather than an approved therapeutic in most jurisdictions.
Dihexa is a synthetic peptide studied in preclinical neuroscience. It is often described as an angiotensin IV analog or derivative. The compound also appears under research codes such as PNB-0408 and N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. It is not an approved drug, and it is not a conventional vitamin or nutrient. In many jurisdictions, material sold as dihexa is handled as a research chemical rather than a medicine or supplement. This classification affects how the material is labeled and distributed.
Chemically, dihexa is a short peptide-like molecule with nonstandard components. Its structure includes tyrosine and isoleucine residues linked to a hexanoic acid group and an aminohexanoic amide segment. This design distinguishes it from endogenous angiotensin IV, though the two are discussed together because of shared origins. Published summaries classify it as a small synthetic peptide with lipophilic features that may influence how it crosses biological barriers in experimental systems. Exact conformational details depend on the specific salt or free base form.
| Property | Value | Notes |
|---|---|---|
| Chemical name | N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide | Common full name in research literature. |
| Class | Synthetic peptide | Modified angiotensin IV analog. |
| Related compound | Angiotensin IV | Parent peptide fragment. |
| Proposed target | HGF/c-Met pathway | Described as an HGF mimetic; not fully confirmed. |
| Development status | Preclinical research | No widely approved clinical use. |
The angiotensin IV connection places dihexa in a family of short peptides studied for effects on central nervous system signaling. Angiotensin IV itself is a metabolite of angiotensin II, and analogs have been explored in cardiovascular and neurological research. Dihexa differs from the natural peptide through structural modifications intended to alter stability and receptor interactions. Published descriptions sometimes call it a hepatocyte growth factor mimetic, although that label reflects proposed activity rather than a confirmed clinical mechanism.
Identity checks for dihexa usually rely on mass spectrometry and chromatographic purity analysis. A lyophilized powder is the common supplied form, and it may appear as a white to off-white solid. Aqueous solubility is limited, so laboratory work often uses an organic solvent such as dimethyl sulfoxide to prepare stock solutions. Because the peptide is not a standard pharmaceutical product, exact specifications can vary between suppliers. Certificates of analysis may accompany a batch, but they are not equivalent to regulatory approval.
Dihexa is a synthetic peptide whose structure is modeled on angiotensin IV. Its chemical name often appears as N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, though vendor and publication naming can differ. The molecule combines a short amino acid sequence with a hexanoic acid group and an amide terminus. It is classed as a small research peptide rather than a conventional drug. Databases may list it under several synonyms, so matching names are important when comparing sources.
In laboratory settings, dihexa is typically handled as a research chemical rather than a pharmaceutical product. Suppliers may provide it as a lyophilized powder or in solution, and purity is often stated as a percentage determined by chromatographic analysis. Because independent verification is uncommon, researchers generally rely on certificates of analysis, which may include high-performance liquid chromatography and mass spectrometry data. The absence of pharmacopeial monographs means that identity, purity, and impurity profiles can vary between batches and suppliers.
Storage recommendations for peptides and peptide-like compounds usually emphasize low temperatures, desiccation, and protection from light. A common practice is to keep dry powder at -20 °C or below and to prepare solutions shortly before use. Repeated freeze-thaw cycles may degrade the material, so aliquoting is often advised. Solubility depends on the solvent; aqueous solubility may be limited, and organic solvents such as dimethyl sulfoxide are sometimes used for stock solutions. Stability data specific to dihexa are sparse, so general peptide handling guidelines are often applied instead.
Analytical confirmation generally combines a separation method with a detection method. Reverse-phase high-performance liquid chromatography can assess purity, while mass spectrometry supports molecular identity. For research-grade material, a certificate of analysis may report a batch-specific purity value, but it does not guarantee biological activity or safety. Regulatory frameworks vary by country; many jurisdictions treat dihexa as a research chemical not intended for human consumption. Purchasers should verify local rules and supplier documentation. The absence of official standards makes independent testing and careful record-keeping important for laboratory work.
The proposed mechanism for dihexa centers on hepatocyte growth factor, or HGF, and its receptor c-Met. HGF signaling is involved in cell growth, survival, and synapse formation. Dihexa has been described as an HGF mimetic or modulator in preclinical literature. Whether it binds c-Met directly, increases HGF availability, or acts through another route remains uncertain. This mechanistic uncertainty is a recurring theme in reviews of the compound, and no single molecular model has been confirmed across independent laboratories.
Research on dihexa has primarily used rodent models and cultured cells. Common endpoints include dendritic spine density, synaptic protein expression, and performance on maze or avoidance tasks. Some studies report improvements in cognitive measures after scopolamine-induced deficits or in aged animals. These findings are interesting but come from a small body of work, and independent laboratories have not consistently replicated all reported effects. Larger, preregistered studies would help clarify which results are robust.
Human data for dihexa remain absent from peer-reviewed clinical literature. As a result, questions about absorption, distribution, metabolism, excretion, and long-term safety are unresolved. Discussions often appear in nootropic forums, where anecdotal reports cannot substitute for controlled trials. Researchers have called for more rigorous pharmacokinetic and toxicological studies before any clinical evaluation. Until such data exist, dihexa is best described as an investigational research compound rather than a proven intervention.
The full name often given is N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. This name indicates a chain containing tyrosine, isoleucine, and a six-carbon amino acid derivative. Databases list a CAS Registry Number and a molecular formula for the compound. The peptide is small compared with proteins, and its structure allows it to be studied in cell cultures and animal models. Exact identity depends on the supplier's synthesis and purification process. Minor impurities can remain after synthesis.
Chemically, dihexa belongs to a broader group of angiotensin IV analogs. Researchers have modified the natural peptide to alter stability, binding, or distribution. Such changes can affect how the molecule behaves in experiments. The parent peptide angiotensin IV is involved in various physiological processes, but the modified analog is not identical to it. Public summaries sometimes blur the distinction between the natural fragment and the synthetic research compound. This distinction matters when interpreting study results.
=== 1997 === 24 August Secrets of the Super Psychics, about Uri Geller and others, made by Open Media 8 September Black Holes, astronomer Phil Charles; the Japanese Ginga (satellite) and V404 Cygni, which orbits a black hole; the William Herschel Telescope in La Palma; Woolsthorpe Manor, south of Grantham, where over 18 months in 1665, Newton deduced the laws of physics; Sir Martin Rees, the Astronomer Royal; vicar John Michell of Thornhill, West Yorkshire; physicist Kip Thorne of Caltech, who made a bet with Stephen Hawking in 1997 - the Thorne–Hawking–Preskill bet; Igor Dmitriyevich Novikov of the Theoretical Astrophysics Center of the University of Copenhagen; Sir Roger Penrose; the Magellanic Clouds are the nearest neighbouring galaxy; the radio galaxy Messier 87 looked at by the Array Operations Center of the National Radio Astronomy Observatory at Sorroco, New Mexico - in March 2021, this would be the first black hole to be photographed, by the Event Horizon Telescope. Narrated by John Hurt, produced by Heather Couper, directed by Richard Smith, made by Pioneer Film And Television Productions, with ABC of Australia and the Discovery Channel.
=== By applied analytical methods === Depending on the required analytical accuracy, researchers may filter data via their analytical instruments. Generally, researchers use only the data from sensitive high-resolution ion microprobe (SHRIMP), inductively coupled plasma mass spectrometry (LA-ICPMS) and thermal ionization mass spectrometry (TIMS) because of their high precision (1–2%, 1–2% and 0.1% respectively) in spot analysis. An older analytical technique, lead-lead evaporation, is no longer used since it cannot determine the U-Pb concordance of the age data.
=== Analogues === Analogues of 4-HO-DPT include dipropyltryptamine (DPT), 5-MeO-DPT, psilocin (4-HO-DMT), 4-HO-DET, 4-HO-DiPT, 4-HO-MPT, 4-HO-EPT, 4-HO-PiPT, and 5-HO-DPT, among others. 4-AcO-DPT is a presumed prodrug of 4-HO-DPT.
Sources: en.wikipedia.org
== Degradation == When a serpin inhibits a target protease, it forms a permanent complex, which needs to be disposed of. For extracellular serpins, the final serpin-enzyme complexes are rapidly cleared from circulation. One mechanism by which this occurs in mammals is via the low-density lipoprotein receptor-related protein (LRP), which binds to inhibitory complexes made by antithrombin, PAI-1, and neuroserpin, causing cellular uptake. Similarly, the Drosophila necrotic serpin is degraded in the lysosome after being trafficked into the cell by the Lipophorin Receptor-1 (homologous to the mammalian LDL receptor family).
==== 2001 White House shooting ==== On February 7, 2001, while Bush was in the residence area of the White House, Robert W. Pickett, standing outside the perimeter fence, discharged a number of shots from a Taurus .38 Special revolver "in the general direction" of the White House. Pickett was shot in the knee by a U.S. Secret Service agent and arrested. Furthermore, he was initially charged with discharging a firearm during a crime, carrying a 10-year mandatory sentence, but following a plea agreement, Pickett instead entered a guilty plea to a firearms violation and an Alford plea to assaulting a federal officer. He was sentenced to three years at the Federal Medical Center, Rochester followed by three years of probation.
=== Pharmacokinetics === There are no clinical studies of the pharmacokinetics of 4-AcO-DMT as of 2024. However, the pharmacokinetics of 4-AcO-DMT have been studied in rodents. The drug was confirmed to act as a prodrug of psilocin similarly to psilocybin (4-PO-DMT). However, given by intraperitoneal injection at equimolar doses, 4-AcO-DMT showed only 70% of the relative bioavailability or total exposure of psilocybin. Hence, 4-AcO-DMT results in modestly lower psilocin levels than psilocybin even when the drugs are given at equivalent doses with adjustment for differences in molecular weight. Along similar lines, the psilocin concentrations with 4-AcO-DMT 15 minutes after administration were 75 to 90% of those of an equimolar dose of psilocybin. The elimination half-life of psilocin was approximately 30 minutes and did not differ between 4-AcO-DMT and psilocybin. Psilocin ester prodrugs like 4-AcO-DMT are cleaved into psilocin by esterase enzymes. A 2025 in-vitro study examined the stability and metabolism of several psilocin ester prodrugs, including 4-AcO-DMT. The results showed that 4-AcO-DMT was rapidly broken down into psilocin by esterase enzymes, with over 99.9% of the prodrug converted within 5 minutes under conditions mimicking the human body (i.e., in human plasma). These findings support the idea that 4-AcO-DMT is quickly and efficiently converted into psilocin before it enters the bloodstream, and that the prodrug itself likely contributes little to the overall pharmacological effect.
In January 2016, Kardashian hosted the Kocktails with Khloé pop culture–themed variety talk show, which aired on the FYI cable channel. The show was cancelled after 14 episodes. Kardashian and business woman Emma Grede launched their clothing line Good American in the same year, and made $1 million in sales on the first day. Good American started by selling jeans ranging from size 00 to 24 and has expanded to a variety of clothes including workout clothes, dresses and a maternity collection. Kardashian starred and produced Revenge Body with Khloé Kardashian, an American reality television series that premiered on the E! cable network, on January 12, 2017.
Sources: en.wikipedia.org
Dihexa is a synthetic peptide analog of angiotensin IV, often described as an HGF mimetic in research literature. It is studied for effects on synaptic connectivity in laboratory models. It is not an approved medication.
No, dihexa is a synthetic compound derived from the structure of angiotensin IV. Angiotensin IV occurs naturally, but dihexa has modifications that change its properties. It is not a standard dietary component.
The main hypothesis is that dihexa interacts with the hepatocyte growth factor system, possibly through c-Met signaling. This interaction may influence synaptogenesis and neuronal plasticity. The exact molecular target remains an active area of study.
It is a synthetic peptide analog of angiotensin IV studied mainly in laboratory and animal research. It is not an approved medicine. Human clinical data are limited.